Research Topics
| M HummerSummaryAffiliation: University of Innsbruck Country: Austria Publications
| Collaborators
|
Detail Information
Publications
Osteoporosis in patients with schizophreniaMartina Hummer
Department of Biological Psychiatry, Innsbruck University Hospital, Austria
Am J Psychiatry 162:162-7. 2005..The authors' goals were to investigate the association between schizophrenia and a decrease in bone mineral density and to get more insight into potential underlying pathophysiological mechanisms...
Sexual disturbances during clozapine and haloperidol treatment for schizophreniaM Hummer
Department of Biological Psychiatry, Innsbruck University Clinics, Austria
Am J Psychiatry 156:631-3. 1999..The aim of this study was to evaluate the frequency and course of sexual disturbances associated with clozapine and haloperidol and their potential influence on compliance with medication regimens in patients with schizophrenia...
Hyperprolactinaemia and antipsychotic therapy in schizophreniaMartina Hummer
Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
Curr Med Res Opin 20:189-97. 2004..A regular risk-benefit discussion will allow the clinician to achieve optimal outcomes in each case...
Attitudes of patients with schizophrenia toward placebo-controlled clinical trialsMartina Hummer
Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
J Clin Psychiatry 64:277-81. 2003..Although much is known about the opinions of professionals concerning this issue, so far nothing is known about the opinions of patients who are most affected by the realization of placebo-controlled clinical trials...
Selection bias in clinical trials with antipsychoticsA Hofer
Department of Biological Psychiatry, University Clinics Innsbruck, Austria
J Clin Psychopharmacol 20:699-702. 2000..A history of noncompliance with previous treatment and the refusal of consent were the most common reasons for not including theoretically eligible patients in a clinical trial...
Risk factors for the development of neuroleptic induced akathisiaC H Miller
Department of Biological Psychiatry, Innsbruck University Clinics, Austria
Eur Neuropsychopharmacol 7:51-5. 1997..75% of all NIA cases occurred within the first three days of antipsychotic treatment. When attempting to determine risk factors for the development of NIA, we found a significant influence of dose increase in the first days of treatment...
Association of olanzapine-induced weight gain with an increase in body fatU Eder
Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
Am J Psychiatry 158:1719-22. 2001..The goal of this study was to explore the pathophysiology of weight gain during treatment with olanzapine for schizophrenia...
QTc variability in schizophrenia patients treated with antipsychotics and healthy controlsMaria A Rettenbacher
Department of Biological Psychiatry, Innsbruck University Hospital, A 6020 Innsbruck, Austria
J Clin Psychopharmacol 25:206-10. 2005....
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effectsAlex Hofer
Department of Biological Psychiatry, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
Eur Psychiatry 20:386-94. 2005..The present cross-sectional study examined the relationships of psychopathology, side effects, and sociodemographic factors with treatment outcomes in terms of patients' quality of life (QOL), functioning, and needs for care...
Patient outcomes in schizophrenia II: the impact of cognitionAlex Hofer
Department of Biological Psychiatry, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
Eur Psychiatry 20:395-402. 2005..Associations have been found between the severity of cognitive deficits and social dysfunction, impairments in independent living, occupational limitations, and disturbances in quality of life (QOL)...
Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorderAlex Hofer
Department of Biological Psychiatry, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
Eur Arch Psychiatry Clin Neurosci 256:246-55. 2006..Our observations suggest that subjective and functional outcomes in highly compliant patients are mainly predicted by psychopathological symptoms and unchangeable sociodemographic variables...
Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysisGeorg Kemmler
Department of General Psychiatry, Innsbruck University Clinics, Anichstrasse 35, A 6020 Innsbruck, Austria
Arch Gen Psychiatry 62:1305-12. 2005..Dropout rates in randomized clinical trials of antipsychotic drugs have consistently been reported to be high, and the use of a placebo-controlled design is hypothesized to be one of the reasons for this...
Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective studyMaria A Rettenbacher
Department of Biological Psychiatry, Medical University Innsbruck, Anichstrasse, Innsbruck, Austria
J Clin Psychopharmacol 26:500-3. 2006..We conclude that antipsychotic-induced elevation of liver enzymes is mostly transient and could be associated with weight gain...
Early changes of plasma lipids during treatment with atypical antipsychoticsMaria A Rettenbacher
Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria
Int Clin Psychopharmacol 21:369-72. 2006..These results are important with regard to the increased risk for cardiovascular complications in patients with schizophrenia...
Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week studyMaria A Rettenbacher
Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria
J Psychopharmacol 21:400-4. 2007..None of these parameters increased significantly in patients treated with amisulpride. This study indicates that treatment with clozapine appears to have a higher risk to lead to metabolic disturbances than amisupride...
Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medicationMaria A Rettenbacher
Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
J Clin Psychiatry 65:1211-8. 2004....
Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effectsAlex Hofer
Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
J Clin Psychiatry 65:932-9. 2004..Factors deemed relevant in this context include severity of symptoms, antipsychotic-induced side effects, sociodemographic variables, and patients' subjective response to medication...
Placebo or active control trials of antipsychotic drugs?W Wolfgang Fleischhacker
Department of Biological Psychiatry, Innsbruck University Clinics, Austria
Arch Gen Psychiatry 60:458-64. 2003..Sample size requirements for various equivalence margins in noninferiority trials are provided. Scientific and ethical arguments should lead to a more frequent use of the active-control noninferiority trial design...
The safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophreniaAlex Hofer
Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
Int J Neuropsychopharmacol 6:201-6. 2003..With regard to side-effects, we could not find any significant difference between groups. Altogether, response and side-effects to clozapine treatment do not seem to be determined by the chronicity of the disorder...
Factors influencing compliance in schizophrenia patientsW Wolfgang Fleischhacker
Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
J Clin Psychiatry 64:10-3. 2003....
Olanzapine induces insulin resistance: results from a prospective studyChristoph F Ebenbichler
Department of Medicine, University of Innsbruck, Innsbruck, Austria
J Clin Psychiatry 64:1436-9. 2003..The aim of this study was to compare glucose metabolism in patients with schizophrenia receiving olanzapine with that in control subjects...
Off-label use of antipsychotic drugsE Weiss
Department of Biological Psychiatry, University of Innsbruck, Austria
J Clin Psychopharmacol 20:695-8. 2000..In classical indications, clozapine was used more frequently (50%) than other antipsychotics. Melperone was primarily prescribed for off-label use...
Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomesW W Fleischhacker
Innsbruck University Clinics, Department of Biological Psychiatry, Austria
Drugs 53:915-29. 1997..Long term maintenance therapy is crucial and continuous monitoring for the development of adverse effects essential...
Switching between second-generation antipsychotics: why and how?Monika Edlinger
Department of Biological Psychiatry, Innsbruck Medical University, Innsbruck, A 6020, Austria
CNS Drugs 19:27-42. 2005..We review the available evidence concerning techniques, problems and consequences when switching from one second-generation antipsychotic agent to another and discuss potential difficulties...
The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective studyChristoph Ebenbichler
Schizophr Res 75:143-6. 2005
Attitudes toward antipsychotics among outpatient clinic attendees with schizophreniaAlex Hofer
Department of Biologic Psychiatry, University Clinics Innsbruck, Austria
J Clin Psychiatry 63:49-53. 2002..CONCLUSION: Our results suggest that special attention should be paid to patients who experience positive symptoms or sedation and to those with relative absence of symptoms, who are therefore tempted to stop taking medication...
The generic alternative in schizophrenia: opportunity or threat?Philippe Nuss
Psychiatry Department, Hopital St Antoine, Paris 75012, France
CNS Drugs 18:769-75. 2004....
Transient hyperproinsulinemia during treatment with clozapine and amisulprideMaria A Rettenbacher
J Clin Psychiatry 65:878-9. 2004
Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patientAlex Hofer
J Clin Psychiatry 64:1267-8. 2003
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialRene S Kahn
Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, Utrecht, Netherlands
Lancet 371:1085-97. 2008..We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia...
Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factorsMarkus Laimer
J Clin Psychopharmacol 25:183-5. 2005
